Luo Xiaoping, Ding Li, Chegini Nasser
Dept. of Obstetrics/Gynecology, University of Florida, Box 100294, Gainesville, FL 32610, USA.
Am J Physiol Endocrinol Metab. 2004 Nov;287(5):E991-E1001. doi: 10.1152/ajpendo.00200.2004. Epub 2004 Jul 20.
Gonadotropin-releasing hormone analog (GnRHa) is used for medical management of endometriosis and premature luteinizing hormone surge during controlled ovarian stimulation. Human endometrium expresses GnRH receptors, and GnRHa alters the expression of transforming growth factor-beta (TGF-beta) and receptors in endometrial cells. Because the diverse biological actions of GnRHa and TGF-beta are mediated in part through the MAPK pathway, we determined whether utilization of MAPK/ERK and transcriptional activation of immediate early genes c-fos and c-jun result in differential regulation of fibronectin, known as key regulator of embryo implantation and endometriosis progression. Using endometrial stromal cells (ESC) and the endometrial epithelial cell line HES, we demonstrated that GnRHa and TGF-beta, in a dose-, time-, and cell-dependent manner, increased the level of phosphorylated ERK1/2 (pERK1/2). GnRH antagonist Antide also increased pERK1/2 induction in ESC and HES, whereas pretreatment reduced GnRHa-induced pERK2 in ESC but not in HES. Cotreatments with GnRHa plus TGF-beta1 did not have an additive or an inhibitory effect on pERK1/2 induction compared with GnRHa or TGF-beta1 action alone. TGF-beta1 and GnRHa increased ERK1/2 nuclear accumulation and inversely regulated the expression of c-fos and c-jun and that of fibronectin in a cell-specific manner. Pretreatment with U-0126, a MEK1/2 inhibitor, blocked basal, as well as GnRHa- and TGF-beta1-induced pERK1/2; however, it differentially affected c-fos, c-jun, and fibronectin expression. In conclusion, the results indicate that GnRHa and TGF-beta signaling through MAPK/ERK results in differential regulation of fibronectin expression in endometrial cells, a molecular mechanism where short- and long-term GnRHa therapy and locally expressed TGF-beta could influence embryo implantation and endometriosis implants, respectively.
促性腺激素释放激素类似物(GnRHa)用于子宫内膜异位症的药物治疗以及控制性卵巢刺激过程中过早出现的促黄体生成素高峰。人子宫内膜表达GnRH受体,且GnRHa会改变子宫内膜细胞中转化生长因子-β(TGF-β)及其受体的表达。由于GnRHa和TGF-β的多种生物学作用部分是通过丝裂原活化蛋白激酶(MAPK)途径介导的,因此我们确定MAPK/细胞外信号调节激酶(ERK)的利用以及即刻早期基因c-fos和c-jun的转录激活是否会导致对纤连蛋白的差异调节,纤连蛋白是胚胎着床和子宫内膜异位症进展的关键调节因子。使用子宫内膜基质细胞(ESC)和子宫内膜上皮细胞系HES,我们证明GnRHa和TGF-β以剂量、时间和细胞依赖性方式增加了磷酸化ERK1/2(pERK1/2)的水平。GnRH拮抗剂Antide也增加了ESC和HES中pERK1/2的诱导,而预处理可降低ESC中GnRHa诱导的pERK2,但对HES无效。与单独使用GnRHa或TGF-β1相比,GnRHa加TGF-β1的联合处理对pERK1/2的诱导没有相加或抑制作用。TGF-β1和GnRHa增加了ERK1/2的核积累,并以细胞特异性方式反向调节c-fos、c-jun和纤连蛋白的表达。用MEK1/2抑制剂U-0126预处理可阻断基础以及GnRHa和TGF-β诱导的pERK1/2;然而,它对c-fos、c-jun和纤连蛋白的表达有不同影响。总之,结果表明通过MAPK/ERK的GnRHa和TGF-β信号传导导致子宫内膜细胞中纤连蛋白表达的差异调节,这是一种分子机制,短期和长期GnRHa治疗以及局部表达的TGF-β可能分别影响胚胎着床和子宫内膜异位症植入物。